Literature DB >> 25244363

Enhanced expression of Toll-like receptors 2 and 4, but not 9, in spleen tissue from patients with visceral leishmaniasis.

R Kumar1, O P Singh, S Gautam, S Nylen, S Sundar.   

Abstract

Toll-like receptor (TLR) signalling is involved in first-line defence against Leishmania parasites by triggering NF-κB activation and downstream production of proinflammatory cytokines. Experimental models of visceral leishmaniasis (VL) support a protective role for TLRs 2, 4 and 9 in host immune responses to Leishmania infection. There are limited data available on expression of these TLRs in human VL, particularly in sites of infection, such as the spleen. This study aimed to determine whether the expression of mRNA encoding the expression of TLRs 2, 4 and 9 was altered in VL and compare expression patterns in splenic biopsies and peripheral blood mononuclear cells.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Toll-like receptors; splenic aspirate; visceral leishmaniasis

Mesh:

Substances:

Year:  2014        PMID: 25244363      PMCID: PMC4246031          DOI: 10.1111/pim.12145

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  20 in total

Review 1.  Toll receptors in innate immunity.

Authors:  J L Imler; J A Hoffmann
Journal:  Trends Cell Biol       Date:  2001-07       Impact factor: 20.808

2.  Toll-like receptor signaling pathways.

Authors:  Gregory M Barton; Ruslan Medzhitov
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

3.  Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection.

Authors:  Tiffany Weinkopff; Anita Mariotto; Gregoire Simon; Yazmin Hauyon-La Torre; Floriane Auderset; Steffen Schuster; Haroun Zangger; Nicolas Fasel; Aldina Barral; Fabienne Tacchini-Cottier
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

4.  Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response.

Authors:  Eric Muraille; Carl De Trez; Maryse Brait; Patrick De Baetselier; Oberdan Leo; Yves Carlier
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

5.  Expression of TLR2 and TLR4 in lesions of patients with tegumentary American leishmaniasis.

Authors:  Felipe Francisco Tuon; Elaine Ribeiro Fernandes; Maria Irma Seixas Duarte; Valdir Sabbaga Amato
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2012 May-Jun       Impact factor: 1.846

Review 6.  Toll-like receptor signaling: a perspective to develop vaccine against leishmaniasis.

Authors:  Rakesh K Singh; Ankita Srivastava; Nisha Singh
Journal:  Microbiol Res       Date:  2012-02-10       Impact factor: 5.415

7.  MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling.

Authors:  Michael J de Veer; Joan M Curtis; Tracey M Baldwin; Joseph A DiDonato; Adrienne Sexton; Malcolm J McConville; Emanuela Handman; Louis Schofield
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

Review 8.  Leishmaniasis: an update of current pharmacotherapy.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2012-12-21       Impact factor: 3.889

9.  Leishmania expressed lipophosphoglycan interacts with Toll-like receptor (TLR)-2 to decrease TLR-9 expression and reduce anti-leishmanial responses.

Authors:  S Srivastava; S P Pandey; M K Jha; H S Chandel; B Saha
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

10.  Leishmaniasis worldwide and global estimates of its incidence.

Authors:  Jorge Alvar; Iván D Vélez; Caryn Bern; Mercé Herrero; Philippe Desjeux; Jorge Cano; Jean Jannin; Margriet den Boer
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

View more
  6 in total

1.  Effects of CD14 and TLR4 on LPS-mediated normal human skin fibroblast proliferation.

Authors:  Hongming Yang; Juncong Li; Yihe Wang; Quan Hu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Transcription of Toll-Like Receptors 2, 3, 4 and 9, FoxP3 and Th17 Cytokines in a Susceptible Experimental Model of Canine Leishmania infantum Infection.

Authors:  Shazia Hosein; Alhelí Rodríguez-Cortés; Damer P Blake; Karin Allenspach; Jordi Alberola; Laia Solano-Gallego
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

Review 3.  Possibilities and challenges for developing a successful vaccine for leishmaniasis.

Authors:  Saumya Srivastava; Prem Shankar; Jyotsna Mishra; Sarman Singh
Journal:  Parasit Vectors       Date:  2016-05-12       Impact factor: 3.876

Review 4.  Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

Authors:  Nicky Didwania; Md Shadab; Abdus Sabur; Nahid Ali
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

5.  Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis.

Authors:  Sarah Forrester; Karin Siefert; Helen Ashwin; Najmeeyah Brown; Andrea Zelmar; Sally James; Dimitris Lagos; Jon Timmis; Mitali Chatterjee; Jeremy C Mottram; Simon L Croft; Paul M Kaye
Journal:  Wellcome Open Res       Date:  2019-12-10

6.  Bioinformatics analysis of gene expression profile data to screen key genes involved in intracranial aneurysms.

Authors:  Tie Guo; Dan Hou; Dan Yu
Journal:  Mol Med Rep       Date:  2019-09-23       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.